7 results
Primary ObjectiveThe primary objective of this study will be to compare the efficacy of infliximab with that of placebo in the prevention of clinical recurrence of CD through Week 76, defined as a composite endpoint that requires endoscopic…
Main Objective:To demonstrate the superiority of galcanezumab versus placebo in the prevention of migraine in (at least) 1 of the following populations with migraine: the overall pediatric population (6 to 17 year-olds) or the adolescent population…
PrimaryTo demonstrate the superiority of galcanezumab versus placebo in the prevention of migraine in an adolescent population (12 to 17 year-olds) with chronic migraineSecondary* To compare galcanezumab with placebo with respect to 50% response…
Primary Objectives* To evaluate the efficacy of golimumab in inducing clinical remission as assessed by the Mayo score,in pediatric participants with moderately to severely active ulcerative colitis (UC).* To evaluate the safety profile of golimumab…
The primary objective of this randomized controlled trial is to investigate the efficacy of dashboard driven dosing of infliximab compared to standard dosing during the induction phase in patients with acute severe ulcerative colitis, as evaluated…
The primary objective is to test the hypothesis that galcanezumab is superior to placebo in the prevention of migraine in patients with treatment-resistant migraine.The key secondary objective are:- To compare galcanezumab with placebo with respect…
To assess safety, tolerability, and PK of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and Budigalimab in subjects with R/M HNSCC.